

AstraZeneca - Key presentations during the 67th ASH Annual Meeting and Exposition

Lead Author	Abstract Title	Presentation Details (ET)
Awan, F et al.	Budget Impact of Fixed Duration Acalabrutinib in Combination with Venetoclax in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States	Abstract #2627 Poster Abstract Session Session 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I 6 December 2025 5:30 PM – 7:30 PM
Cheah, C et al.	Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the Phase 3 ECHO trial	Abstract #3578 Poster Abstract Session Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II 7 December 2025 6:00 PM – 8:00 PM
Ghia, P et al.	Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY	Abstract #3898 Poster Abstract Session Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II 7 December 2025 6:00 PM – 8:00 PM
Hawkes, E et al.	Acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL): Results from the phase 2 TrAVeRse study	Abstract #884 Oral Abstract Session Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL 8 December 2025 3:00 PM – 03:15 PM
Hou, J-Z et al.	Real-world incidence of treatment-emergent (TE) cardiovascular (CV) events among chronic lymphocytic (CLL)/small lymphocytic lymphoma (SLL) patients receiving acalabrutinib (acala) or zanubrutinib (zanu) monotherapy	Abstract #4506 Poster Abstract Session Session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II 7 December 2025 6:00 PM – 8:00 PM
Seymour, JF et al.	A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the Phase 3 AMPLIFY trial	Abstract #2118 Poster Abstract Session Session 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I 6 December 2025 5:30 PM – 7:30 PM

Lead Author	Abstract Title	Presentation Details (ET)
Wang, ML et al.	Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up	Abstract #885 Oral Abstract Session Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL 8 December 2025 3:15 PM – 3:30 PM
Ultomiris (ravulizumab)		
Schoettler, M et al.	Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab	Abstract #1052 Oral Abstract Session Session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects 8 December 2025 4:45 PM – 05:00 PM
Chaudhury, S et al.	Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab	Abstract #4266 Poster Abstract Session Session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II 7 December 2025 6:00 PM – 8:00 PM
Sherrard, H et al.	Safety of ravulizumab use in pregnancy: Insights from a global pharmacovigilance analysis	Abstract #4458 Poster Abstract Session Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II 7 December 2025 6:00 PM – 8:00 PM
Gandhi, S et al.	Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: Insights from the international PNH registry	Abstract #6238 Poster Abstract Session Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III 8 December 2025 6:00 PM – 8:00 PM
Fasenra (benralizumab)		
Klion et al.	Efficacy and safety of benralizumab in patients with hypereosinophilic syndrome: Results from the Phase 3 natron study	Abstract #79 Oral Abstract Session Session 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome 06 December, 2025 9:30 AM - 9:45 AM

Fasenra (benralizumab)		
Klion et al.	Patient perspectives on the burden of hypereosinophilic syndrome: Results from the Phase 3 natron interview sub-study	Abstract #4465 Poster Presentation Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II 07 December, 2025 6:00 PM - 8:00 PM
Voydeya (danicopan)		
Kulasekararaj, A et al.	Danicopan add-on therapy demonstrates positive efficacy and safety outcomes in advanced age adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: A sub-analysis of the phase 3 ALPHA trial	Abstract #949 Oral Abstract Session Session 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care 8 December 2025 2:45 PM – 03:00 PM
Surovatamig		
Aldoss, I et al.	Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated results from the Phase 1/2 SYRUS study	Abstract #3345 Poster Abstract Session Session 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II 7 December 2025 6:00 PM – 8:00 PM
Cheah, C et al.	SOUNDTRACK-B: A Phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell Non-Hodgkin lymphoma	Abstract #3747 (TiP) Poster Abstract Session Session 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II 7 December 2025 6:00 PM – 8:00 PM
Hou, JZ et al.	Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) follicular lymphoma (FL)	Abstract #1005 Oral Abstract Session Session 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Follicular Lymphoma 8 December 2025 5:00 PM – 5:15 PM
Kim, TM et al.	Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-negative complete responses in	Abstract #5514 Poster Abstract Session Session 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III 8 December 2025 6:00 PM – 8:00 PM

Surovatamig		
	relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies	
AZD0120		
Du, J et al.	A dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma	Abstract #258 Oral Abstract Session Session 655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma 6 December 2025 2:15 PM – 2:30 PM
Richard, S et al.	Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary results from the DURGA-1 Phase 1b/2 study	Abstract #269 Oral Abstract Session Session 704. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma 6 December 2025 3:00 PM – 3:15 PM
Feng, J et al.	One-year follow-up of CD19/BCMA dual-targeting FasTCAR-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus	Abstract #2384 Poster Abstract Session Session 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I 6 December 2025 5:30 PM – 7:30 PM
Lentzsch, S et al.	ALACRITY: A Phase 1b/2 Study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in Participants with Relapsed or Refractory Light Chain Amyloidosis (AL)	Abstract #8236 ePublication 3 November 2025
AZD4512		
Han, H et al.	AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies	Abstract #3296 Poster Abstract Session Session 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II 7 December 2025 6:00 PM – 8:00 PM